Uncategorized
Valeant to divest Paragon
Valeant Pharmaceuticals has agreed to divest Paragon Holdings I Inc. to restore competition in the gas-permeable button market, according to the Federal Trade Commission.It was alleged that Valeant’s acquisition of Paragon Holdings, which included the wholly owned subsidiaries Paragon Vision Sciences Inc. and CRT Technology Inc., violated Section 7 of the Clayton Act and Section 5 of the FTC Act by lessening competition in the markets for polymer discs, or buttons, used to make orthokeratology, large-diameter scleral and general vision correction contact lenses.